As of 2:32 PM on the 6th, Pamisell is trading at 19,450 KRW, down 0.26% from the previous day. This represents a 12.78% decline compared to June 12. Pamisell is known as a bio-pharmaceutical company that developed the world's first stem cell therapy.
Today, foreigners are tentatively recorded as net buyers of 7,000 shares. Over the past five days, individual investors have net purchased 182,963 shares, while foreigners and institutions have net sold 294,142 shares and 1,479 shares, respectively.
On July 2, Pamisell was a market topic with the news of winning a lawsuit to cancel the rejection of conditional approval for 'Cellgram,' leading to a rise in its stock price.

[Table] Foreigners and Institutions Net Trading Volume (Unit: shares)

※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Clutching a Stolen Dior Bag, Saying "I Hate Being Poor but Real"... The Grotesque Con of a "Human Knockoff" [Slate]](https://cwcontent.asiae.co.kr/asiaresize/183/2026021902243444107_1771435474.jpg)
